Intro

This chapter explores the challenges of hemophagocytic lymphohistiocytosis (HLH) and highlights a study on the effectiveness of ruxolitinib in treatment. It emphasizes the superiority of JAK1-2 inhibition over gamma interferon blockade in mitigating hypercytokinemia and discusses implications for future clinical trials.